NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended... The product is intended for basal insulin treatment of diabetes mellitus.
- Mechanism
- Curator reviewed
NN344 binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of NN344 to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 1 and 2.Curator reviewed
- Code names
- NN344
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with NN344, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account